August 21, 2014 10:21 PM ET


Company Overview of Glaxosmithkline Biologicals S.A.

Company Overview

Glaxosmithkline Biologicals S.A. researches, develops, manufactures, and supplies vaccines. Its vaccination products are used to tackle various diseases, such as rabies, diphtheria, tetanus, and yellow fever, as well as polio, measles, mumps, and rubella and hepatitis B. Glaxosmithkline Biologicals S.A. was formerly known as SmithKline Beecham Biologicals S.A. and changed its name to GlaxoSmithKline Biologicals S.A. in 2000. The company was founded in 1945 and is based in Rixensart, Belgium. Glaxosmithkline Biologicals S.A. operates as a subsidiary of GlaxoSmithKline plc.

Rue de l'institut 89

Rixensart,  1330


Founded in 1945


32 2 656 81 11


32 2 656 80 00

Key Executives for Glaxosmithkline Biologicals S.A.

Chief Executive of GlaxoSmithKline PLC
Age: 49
Compensation as of Fiscal Year 2014.

Glaxosmithkline Biologicals S.A. Key Developments

Arabio Signs Agreement with GSK for Local Production of Vaccines

GSK Vaccines and Glaxo Saudi Arabia Limited (GSAL) have signed an agreement with ARABIO under which a number of vaccines will be manufactured in Saudi Arabia. The vaccines to be manufactured locally include Infanrix hexa - used in the prevention of Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b (Hib) - and Rotarix - used in the prevention of symptoms caused by rotavirus infection. Under the agreement, GSK Vaccines will transfer knowledge related to the vaccines to GSAL and ARABIO.

GSK Vaccines Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013

GSK Vaccines Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013 . Venue: Centre Covencions International Barcelona, Plaça de Willy Brandt, 11-14, 08019 Barcelona, Spain.

GlycoVaxyn AG and GlaxoSmithKline Biologicals Sign Bacterial Vaccine Development Partnership

GlycoVaxyn and GlaxoSmithKline Biologicals (GSK) have signed a research partnership for the development of new bacterial vaccines. The collaboration, planned for three years, will leverage GlycoVaxyn's bio-conjugation technology in developing vaccines against a range of undisclosed bacterial pathogens. As per the deal, GlycoVaxyn will obtain an upfront payment along with an equity investment in addition to milestone payments and royalties on licensed candidates. During the collaboration, GSK has an option to acquire exclusive license on the vaccine targets, extend the period of collaboration and expand the capacity of the partnership.

Similar Private Companies By Industry

Company Name Region
S.A. Ajinomoto OmniChem N.V. Europe
Janssen Animal Health BVBA Europe
Madaus Pharma S.A. Europe
SCS Boehringer Ingelheim Comm.V. Europe
elbion NV Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Glaxosmithkline Biologicals S.A., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at